MARC JOSEPH GURWITH, M.D.
Osteopathic Medicine at Alma St, Menlo Park, CA
License number
California MD031400E
Category
Osteopathic Medicine
Type
Infectious Disease
Address
Address
2
1100 Alma St STE 109, Menlo Park, CA 94025
13157 La Paloma Rd, Los Altos, CA 94022
13157 La Paloma Rd, Los Altos, CA 94022
Phone
(650) 823-1548
(650) 847-1075
(650) 847-1075
Professional information
Cmo At Paxvax
Position:
CMO at PaxVax
Location:
San Francisco Bay Area
Industry:
Biotechnology
Work:
PaxVax
- Menlo Park, CA since May 2010
-
CMO
VaxGen
Oct 2001 - Nov 2007
-
SVP Medical Affairs and CMO
Education:
Temple University - James E. Beasley School of Law 1987 - 1991
JD, law Harvard Medical School 1961 - 1965
MD Yale University 1957 - 1961
BA, philosophy
JD, law Harvard Medical School 1961 - 1965
MD Yale University 1957 - 1961
BA, philosophy
Dr. Marc J Gurwith, Menlo Park CA - MD (Doctor of Medicine)
Specialties:
Infectious Disease Medicine, Medical Microbiology
Address:
1100 Alma St STE 109, Menlo Park 94025
(650) 823-1548 (Phone)
1355 Bogue St STE B220, East Lansing 48824
(650) 823-1548 (Phone)
1355 Bogue St STE B220, East Lansing 48824
Certifications:
Infectious Disease, 1980, Internal Medicine, 1973, Medical Microbiology, 1980
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Harvard Medical School
Graduated: 1965
Stanford
Harvard Medical School
Graduated: 1965
Stanford
Marc Joseph Gurwith, Menlo Park CA
Specialties:
Infectious Disease Specialist
Address:
1100 Alma St, Menlo Park, CA 94025
Treatment Of Sle With Dehydroepiandrosterone
US Patent:
6552010, Apr 22, 2003
Filed:
Nov 10, 2000
Appl. No.:
09/710754
Inventors:
Kenneth E. Schwartz - San Mateo CA
Marc J. Gurwith - Los Altos CA
Marc J. Gurwith - Los Altos CA
Assignee:
Genelabs Technologies, Inc. - Redwood City CA
International Classification:
A61K 3156
US Classification:
514177, 514170, 514171
Abstract:
This invention provides a method of treating systemic lupus erythematosus (SLE) with (DHEA) and a related pharmaceutical product.
Dhea Composition And Method
US Patent:
7045513, May 16, 2006
Filed:
Mar 16, 2000
Appl. No.:
09/526802
Inventors:
Jagdish Parasrampuria - Bridgewater NJ, US
Maxine B. Yonker - Emerald Hills CA, US
Kenneth E. Schwartz - San Mateo CA, US
Marc J. Gurwith - Los Altos CA, US
Maxine B. Yonker - Emerald Hills CA, US
Kenneth E. Schwartz - San Mateo CA, US
Marc J. Gurwith - Los Altos CA, US
Assignee:
Genelabs Technologies, Inc. - Redwood City CA
International Classification:
A61K 31/56
US Classification:
514170, 514169, 514177, 514178, 514180
Abstract:
Disclosed are improved pharmaceutical formulations comprising dehydroepiandrosterone (DHEA), enriched in selected polymorphic forms, for therapeutic applications. In one embodiment, the formulation comprises, in solid form, DHEA, at least 85% of which is present as a single polymorph selected from the form I polymorph or the form II polymorph, and at least one pharmaceutical excipient. Methods for making and using such compositions are also disclosed.
Dhea Composition And Method
US Patent:
2006023, Oct 19, 2006
Filed:
Mar 21, 2006
Appl. No.:
11/387111
Inventors:
Jagdish Parasrampuria - Bedminster NJ, US
Maxine Yonker - Emerald Hills CA, US
Kenneth Schwartz - San Mateo CA, US
Marc Gurwith - Los Altos CA, US
Maxine Yonker - Emerald Hills CA, US
Kenneth Schwartz - San Mateo CA, US
Marc Gurwith - Los Altos CA, US
International Classification:
A61K 31/57
US Classification:
514177000
Abstract:
Disclosed are improved pharmaceutical formulations comprising dehydroepiandrosterone (DHEA), enriched in selected polymorphic forms, for therapeutic applications. In one embodiment, the formulation comprises, in solid form, DHEA, at least 85% of which is present as a single polymorph selected from the form I polymorph or the form II polymorph, and at least one pharmaceutical excipient. Methods for making and using such compositions are also disclosed.
Treatment Of Sle With Dehydroepiandrosterone
US Patent:
2003018, Sep 25, 2003
Filed:
Jan 8, 2003
Appl. No.:
10/340267
Inventors:
Kenneth Schwartz - San Mateo CA, US
Marc Gurwith - Los Altos CA, US
Marc Gurwith - Los Altos CA, US
Assignee:
Genelabs Technologies, Inc.
International Classification:
A61K031/57
US Classification:
514/178000
Abstract:
This invention provides a method of treating systemic lupus erythematosus (SLE) with (DHEA) and a related pharmaceutical product.